Skip to content

Study · Randomized controlled trial · n = 96 · 2020

7 results

Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12.

Ikeda S, Nakamura E, Narusawa K, Fukuda F, Matsumoto H, Nakai K, Sakata T, Yoshioka T, Fujino Y, Sakai A

Journal of bone and mineral metabolism11 Jul 2019Cited by 16 (Europe PMC)

PMID31297652 (opens in a new tab)DOI10.1007/s00774-019-01023-x (opens in a new tab)PepBankPUB-31297652
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with new osteoporotic vertebral fractures, vertebral collapse progressed in both groups without a significant teriparatide versus alendronate difference.

    In plain wordsIn women with new osteoporotic vertebral fractures, vertebral collapse progressed similarly with teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeVertebral collapse
    Study

    n = 96

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Once weeklyAs given in this study (human).

    Source sentences

    Summary
    Vertebral collapse progressed over time in both groups, with no significant difference between the groups.
    3 context sentences
    Summary · context
    The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week af…
    Summary · context
    Patients were randomly allocated to the teriparatide and alendronate groups.
    Summary · context
    Each group consisted of 48 subjects.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with new osteoporotic vertebral fractures, pain on rising improved in both groups without a significant teriparatide versus alendronate difference.

    In plain wordsIn women with new osteoporotic vertebral fractures, pain on rising improved similarly with teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePain on rising from lying
    Study

    n = 96

    Comparator
    Alendronate
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Once weeklyAs given in this study (human).

    Source sentences

    Summary
    Pain on rising up from lying position, turning over in bed, and resting in the lying position improved over time in both groups, with no significant difference between the groups.
    3 context sentences
    Summary · context
    The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week af…
    Summary · context
    Patients were randomly allocated to the teriparatide and alendronate groups.
    Summary · context
    Each group consisted of 48 subjects.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with new osteoporotic vertebral fractures, pain turning in bed improved similarly with teriparatide and alendronate.

    In plain wordsIn women with new osteoporotic vertebral fractures, pain turning in bed improved similarly with teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePain turning in bed
    Study

    n = 96

    Comparator
    Alendronate
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Once weeklyAs given in this study (human).

    Source sentences

    Summary
    Pain on rising up from lying position, turning over in bed, and resting in the lying position improved over time in both groups, with no significant difference between the groups.
    3 context sentences
    Summary · context
    The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week af…
    Summary · context
    Patients were randomly allocated to the teriparatide and alendronate groups.
    Summary · context
    Each group consisted of 48 subjects.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with new osteoporotic vertebral fractures, pain at rest while lying improved similarly with teriparatide and alendronate.

    In plain wordsIn women with new osteoporotic vertebral fractures, pain at rest while lying improved similarly with teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePain resting while lying
    Study

    n = 96

    Comparator
    Alendronate
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Once weeklyAs given in this study (human).

    Source sentences

    Summary
    Pain on rising up from lying position, turning over in bed, and resting in the lying position improved over time in both groups, with no significant difference between the groups.
    3 context sentences
    Summary · context
    The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week af…
    Summary · context
    Patients were randomly allocated to the teriparatide and alendronate groups.
    Summary · context
    Each group consisted of 48 subjects.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with new osteoporotic vertebral fractures, BMD increases did not differ significantly between teriparatide and alendronate.

    In plain wordsIn women with new osteoporotic vertebral fractures, bone density increases did not differ significantly between teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar BMD increase
    Study

    n = 96

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Once weeklyAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in increase in BMD and delayed union.
    4 context sentences
    Summary · context
    Lumbar bone mineral density (BMD) at baseline and week 12 and the rate of delayed union at week 12 were also compared.
    Summary · context
    The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week af…
    Summary · context
    Patients were randomly allocated to the teriparatide and alendronate groups.
    Summary · context
    Each group consisted of 48 subjects.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with new osteoporotic vertebral fractures, delayed union did not differ significantly between teriparatide and alendronate.

    In plain wordsIn women with new osteoporotic vertebral fractures, delayed bone healing did not differ significantly between teriparatide and alendronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeDelayed union
    Study

    n = 96

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Once weeklyAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in increase in BMD and delayed union.
    3 context sentences
    Summary · context
    The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week af…
    Summary · context
    Patients were randomly allocated to the teriparatide and alendronate groups.
    Summary · context
    Each group consisted of 48 subjects.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with new osteoporotic vertebral fractures, teriparatide improved quality of life more than alendronate at week 12.

    In plain wordsIn women with new osteoporotic vertebral fractures, teriparatide improved quality of life more than alendronate at week 12.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseQuality of life at week 12
    Study

    n = 96

    Comparator
    Alendronate
    Outcome group
    Quality of life · Whole body
    Studied dose
    Once weeklyAs given in this study (human).

    Source sentences

    Summary
    QOL in the teriparatide group showed significant improvement in comparison with that in the alendronate group at week 12.
    3 context sentences
    Summary · context
    The objective of the present multicenter randomized study was to compare weekly teriparatide with alendronate in their inhibition of vertebral collapse, effects on delayed union, pain relief, and improvement of quality of life (QOL) in women with new osteoporotic vertebral fractures within 1 week af…
    Summary · context
    Patients were randomly allocated to the teriparatide and alendronate groups.
    Summary · context
    Each group consisted of 48 subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.